Investigation Report on China Raloxifene Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||333636|
|出版日期||內容資訊||英文 30 Pages
|Raloxifene的中國市場分析 Investigation Report on China Raloxifene Market, 2010-2019|
|出版日期: 2015年06月25日||內容資訊: 英文 30 Pages||
根據統計資料，全球2億人以上的人為骨質疏鬆症所苦。若只限於中國國內的50歲女性，骨質降低或骨質疏鬆症的罹患率達到50％ (但60歲以上的女性的情況為30∼50％)。Raloxifene是治療骨質疏鬆症的非荷爾蒙劑，自1997年的上市以來，在全球各國急速普及。中國在2003年上市，2005∼2014年也以年複合成長率(CAGR) 約14％的速度擴大銷售額。
According to the statistics, over 200 million people suffer from osteoporosis in the world. Among women aged 50 and above in China, 50% have low bone mass or osteoporosis while this figure is 30%-50% among women aged 60 and above.
Raloxifene (raloxifene hydrochloride), a non-hormone drug against bone resorption, belongs to the second generation of selective estrogen receptor modulator (SERMs). Different from traditional estrogen replacement therapy (ERT) or hormone replacement therapy (HRT), raloxifene can not only prevent postmenopausal women from osteoporosis but also effectively increase bone mass and bone density so as to treat postmenopausal osteoporosis and prevent osteoporotic fracture.
When raloxifene made by Eli Lilly under the trade name of Evista entered the market in 1997, its global sales value in the first year reached up to 285 million, making it the second most successful product of Eli Lilly. However, raloxifene's annual sales value has been fluctuating around USD 1 billion after it reached its sales peak of USD 1.091 billion in 2007.
Raloxifene made by local enterprises came into the market after Evista entered China in Oct. 2003 and raloxifene's CAGR was about 14% during the period of 2005-2014 according to CRI's survey. Raloxifene enjoys a vast demand in China. Currently, raloxifene in the Chinese market are monopolized by the following three companies: Eli Lilly and Company (Spain), Eli Lilly and Company (UK) and Jiangsu Hengrui Medicine Co., Ltd, among which Eli Lilly and Company (Spain) has the largest market share of 86% for sales value in 2014.
Raloxifene market in China is expected to grow in the next few years.
Readers can get at least the following information from this report:
The author suggests the following groups of people purchase this report: